Showing 1321-1330 of 3047 results for "".
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- Measuring ctDNA May Lead to Alternative Treatment Options and Better Outcomes in Advanced Melanomahttps://practicaldermatology.com/news/measuring-ctdna-may-lead-to-alternative-treatment-options-and-better-outcomes-in-advanced-melanoma/2462040/Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study found that measuring ctDNA in the blood of patients with BRAF wild-type (BRAF WT) s
- Revealed: Key Genes That May Up Nodular Melanoma Riskhttps://practicaldermatology.com/news/revealed-key-genes-that-may-up-nodular-melanoma-risk/2462038/New research sheds light on gene variants which may contribute to higher risk for nodular melanoma. Nodular melanoma accounts for around 14% of invasive melanoma cases, but the aggressive subtype is the largest contributor to melanoma deaths. “Nodular melanoma is often detect
- AD Pipeline Update: FDA Rejects Lilly’s Lebrikizumab Due to Third-Party Manufacturing Issueshttps://practicaldermatology.com/news/ad-pipeline-update-fda-rejects-lillys-lebrikizumab-due-to-third-party-manufacturing-issues/2462037/The U.S. Food and Drug Administration (FDA) did not approve Eli Lilly's lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis due to findings during an inspection of a contract manufacturer. The letter cited findings
- Smart Ring May Objectively Measure Scratching Intensityhttps://practicaldermatology.com/news/smart-ring-may-objectively-measure-scratching-intensity/2462015/A new wearable device may objectively measure the intensity of scratching. Akhil Padmanabha, a PhD student in Carnegie Mellon University's (CMU)
- A Livestock Drug Delivered Via Nanoparticles May Help Eradicate Acnehttps://practicaldermatology.com/news/a-livestock-drug-delivered-via-nanoparticles-may-help-eradicate-acne/2462004/Australian scientists may have found an effective treatment for acne that is delivered via tiny nanoparticles. In a study led by the
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co. Ltd. for Qbrexza in South Korea, Other Asian Nationshttps://practicaldermatology.com/news/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd-for-qbrexza-in-south-korea-other-asian-nations/2461983/Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations. Maruho Co., Ltd. is Journey’s exclusive licensing partner that developed and is commercializing Qbrexza (Rapifort) in Japan.&n